Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435299 | 1.00 | MAPT (0.67) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL57125 | 0.87 | HTT (0.68) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL11511746 | 0.85 | PDE7A (0.71) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL10965789 | 0.83 | MAPT (0.61) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL527567 | 0.82 | HTT (0.72) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL29441283 | 0.82 | HTT (0.72) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL22069645 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL1332216 | 0.82 | MAPT (0.60) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL14477748 | 0.82 | HSD17B10 (0.56) | MAPTSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL2766450 | 0.82 | MAPT (0.63) | MAPTSMN1; SMN2HPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478291-A | Preparation method of monomer diamine compound of polyimide | 西安爱德克美新材料有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-103172536-A | Preparation method of 4-amino-2,6-dichloro-alpha-(4-chlorphenyl) benzyl cyanide | CHANGZHOU YABANG QH PHARMACHEM CO LTD | 2013-06-26 | — | — | CN | claimed |
| CN-117362642-A | Polyimide with high Tg and low dielectric constant, and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2024-01-09 | — | — | CN | disclosed |
| CN-114478291-A | Preparation method of monomer diamine compound of polyimide | 西安爱德克美新材料有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478291-A | Preparation method of monomer diamine compound of polyimide | 西安爱德克美新材料有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-110088092-A | Compounds, methods of obtaining compounds, pharmaceutical compositions, uses of compounds and methods of treating psychiatric and/or sleep disorders | 艾奇实验室制药有限公司 | 2019-08-02 | — | — | CN | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| CN-102548557-B | Compounds for reducing beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2014-12-24 | — | — | CN | disclosed |
| CN-103130657-B | Synthetic method of 2-chloro-4-aminophenol | JIANGSU FLAG CHEMICAL INDUSTRY CO LTD | 2014-12-10 | — | — | CN | disclosed |
| EP-0325892-A2 | Process for the preparation of halogenated primary amines | CIBA-GEIGY AG (CH) | 1989-08-02 | — | — | EP | disclosed |
| EP-0281242-A1 | Beta-alkylmelatonins | ELI LILLY AND COMPANY (US) | 1988-09-07 | — | — | EP | disclosed |
| CN-88100478-A | alkyl melatonin | — | 1988-08-17 | — | — | CN | disclosed |
| EP-0076220-B1 | PROCESS FOR THE HYDROLYSIS OF ARYL ALIPHATIC ETHERS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-08-07 | — | — | EP | disclosed |
| EP-0076220-A1 | Process for the hydrolysis of aryl aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1983-04-06 | — | — | EP | disclosed |
| US-4225611-A | TREATMENT OF ULCEROUS GASTRO-DUODENAL DISORDERS | CHOAY S.A. (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4126626-A | DYES, POLYESTERS | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-4059627-A | HYDROGENATION OF CHLORINATED NITRO AROMATIC, NOBLE METAL CATALYST, THIOETHER | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-22 | — | — | US | disclosed |
| US-3989756-A | RANEY CATALYST, DEHALOGENATION INHIBITOR | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | MAPT 15/4885SMN1; SMN2 760/4885HPGD 586/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | MAPT 15/4885SMN1; SMN2 760/4885HPGD 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.